Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Jul 14, 2010


Myriad Genetics announced last week the appointment of Gary King to the newly created position of executive vice president of international operations. King will oversee Myriad's expansion into Europe and other international markets. His immediate focus will be commercializing Myriad's eight diagnostic products in major market countries of Germany, France, Italy, Spain, and the United Kingdom, the company said.

Prior to joining Myriad, King was CEO of the international biotech firm AverDx. King also served as the VP of international operations at Biosite and as division director in Japan for Guidant.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.